Oncology Clinical Trial Finder

Breast Cancer

Active, not recruiting • Phase II • Stage IV • ER positive • PR positive • HER2 negative • Post-Menopausal • Brain Metastases absent • Interventional

The following is imported from ClinicalTrials.gov:

A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer

This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone receptor positive breast cancer.

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. In this research study, The investigators are evaluating the safety and effectiveness of Eribulin mesylate with or without Pembrolizumab in metastatic hormone receptor positive breast cancer. The FDA (the U.S. Food and Drug Administration) has not approved the combination of Pembrolizumab and Eribulin mesylate for Breast Cancer. The FDA has not approved Pembrolizumab for this specific type of breast cancer but it has been approved in the United States for other diseases. The FDA has approved Eribulin mesylate as a treatment option for this type of breast cancer. Pembrolizumab is a medicine that may treat cancer by working with the immune system. The immune system is the body's natural defense against disease. The immune system sends types of cells called "T cells" throughout the body to detect and fight infections and diseases, including cancer. For some types of cancer, the T cells do not work as they should and are prevented from attacking the tumors. Pembrolizumab is thought to work by blocking a protein in the T cells called PD-1 ("programmed death 1"), which then may allow these cells and other parts of the immune system to attack tumors. Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying. The combination of Pembrolizumab and Eribulin mesylate is investigational. The study drugs, when given separately, work in different ways to stop the cancer cells from growing and spreading. However, it is not known if giving the two study drugs at the same time will have a better anti-cancer effect than giving each treatment on its own.

Breast Cancer

Study Design

Study type:


Estimated enrollment:

90 participants

Actual study start date:

March 22, 2017

Eligibility Criteria

Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention

  • Eribulin Mesylate

  • Pembrolizumab

Trial Information at Site

Last Updated:

Trial Information

ClinicalTrial.gov ID:

Active, not recruiting

Estimated Enrollment:


Last Updated:


Principal Investigator

Sara Tolaney, MD MPH

Trial Sponsor

Dana-Farber Cancer Institute

Study Locations (3)

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States


© 2023 Outcomes4Me Inc. All rights reserved.